-
公开(公告)号：JP2013538860A
公开(公告)日：2013-10-17
申请号：JP2013531959
申请日：2011-10-03
Applicant: ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. , ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Inventor： ロバート・ハーシュバーグ , ジョージ・クウコス , グレゴリー・ディーチ , アンドレア・ファッチャベーネ , クリスティ・マンジャーレス , トレッサ・ディ・ランドール
IPC: A61K31/55 , A61K9/08 , A61K9/19 , A61K31/675 , A61K31/704 , A61K31/7068 , A61K45/00 , A61K47/40 , A61P35/00
CPC classification number: A61K31/55 , A61K9/0019 , A61K9/1271 , A61K31/675 , A61K31/704 , A61K31/7068 , A61K45/06 , A61K47/6951 , B82Y5/00 , A61K2300/00
Abstract: 本発明は、一般に、ＴＬＲアゴニスト（好ましくは、ＴＬＲ８アゴニスト）の製剤および様々な疾患の治療（癌を治療するための組み合わせ治療を含む）におけるその使用に関する。
-
公开(公告)号：JP2013538859A
公开(公告)日：2013-10-17
申请号：JP2013531958
申请日：2011-10-03
Inventor： ロバート・ハーシュバーグ
IPC: A61K31/55 , A61K9/127 , A61K9/20 , A61K45/00 , A61P11/02 , A61P11/06 , A61P17/04 , A61P27/02 , A61P37/08 , A61P43/00
CPC classification number: A61K31/55 , A61K9/0043
Abstract: 本発明は概して、アレルギー性疾患（例えば、アレルギー性鼻炎）の治療または予防に用いるためのＴＬＲ８アゴニスト、ＶＴＸ−３７８に関する。
Abstract translation: 本发明一般涉及TLR8激动剂VTX-378，用于治疗或预防过敏性疾病，包括过敏性鼻炎。
-
公开(公告)号：US09242964B2
公开(公告)日：2016-01-26
申请号：US14016951
申请日：2013-09-03
Applicant: VentiRx Pharmaceuticals, Inc. , Array BioPharma, Inc.
Inventor： James Jeffry Howbert , Gregory Dietsch , Robert M. Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
IPC: A61K31/55 , C07D223/16 , C07D403/14 , A61K31/4025 , C07D401/04 , C07D403/04 , C07D403/10 , C07D401/14
CPC classification number: C07D223/16 , A61K31/4025 , A61K31/55 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
-
公开(公告)号：US20180303845A1
公开(公告)日：2018-10-25
申请号：US15771662
申请日：2016-11-02
Applicant: VentiRx Pharmaceuticals, Inc.
Inventor： Gregory N. DIETSCH
IPC: A61K31/55 , A61K39/395 , A61K45/06 , C07K16/28 , A61K31/704 , A61P35/00 , C07K16/30
CPC classification number: A61K31/55 , A61K31/704 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , A61K2039/572 , A61K2039/585 , A61K2300/00 , A61P35/00 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/732 , C07K2317/76
Abstract: The application relates to methods of inducing antitumor immune responses in a subject having cancer. In some embodiments, methods are provided for administering to a subject in need thereof a TLR8 agonist and a PD1-1/PD-L1 antagonist, optionally including one or more additional therapeutic agents.
-
公开(公告)号：US20160129010A1
公开(公告)日：2016-05-12
申请号：US14817291
申请日：2015-08-04
Applicant: VentiRx Pharmaceuticals, Inc. , Array BioPharma, Inc.
Inventor： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , Joseph P. Lyssikatos , Brad Newhouse , Hong-Woon Yang
IPC: A61K31/55
CPC classification number: A61K31/55 , C07D223/14 , C07D223/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/04 , C07D405/10
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
Abstract translation: 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，感染性疾病，炎症性疾病，移植排斥反应和移植物抗宿主病。
-
Patent Agency Ranking
公开(公告)号：US20140234376A1
公开(公告)日：2014-08-21
申请号：US14180939
申请日：2014-02-14
Applicant: Array BioPharma, Inc. , VentiRx Pharmaceuticals, Inc.
Inventor： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , Joseph P. Lyssikatos , Brad Newhouse , Hong-Woon Yang
IPC: C07D223/16 , C07D405/04 , C07D401/04 , C07D405/10 , C07D401/12 , C07D403/10
CPC classification number: A61K31/55 , C07D223/14 , C07D223/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/04 , C07D405/10
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
Abstract translation: 提供了可用于通过Toll样受体TLR7和/或TLR8调节信号传导的组合物和方法。 组合物和方法可用于治疗或预防疾病，包括癌症，自身免疫性疾病，感染性疾病，炎性疾病，移植物排斥反应和移植物宿主病。
-
公开(公告)号：US20170027954A1
公开(公告)日：2017-02-02
申请号：US15290873
申请日：2016-10-11
Applicant: VENTIRX PHARMACEUTICALS, INC.
Inventor： Robert Hershberg
CPC classification number: A61K31/55 , A61K39/39 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2300/00 , C07K16/2863 , C07K16/2887 , C07K16/3046 , C07K16/32 , C07K2317/21 , C07K2317/24 , C07K2317/732
Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
Abstract translation: 本申请涉及在接受治疗性单克隆抗体治疗的受试者中增加抗体依赖性细胞毒性的方法。 在一些实施方案中，提供了用于施用以治疗有需要的受试者与ADCC增强子分子结合的治疗性抗体的方法。
-
公开(公告)号：US20140142086A1
公开(公告)日：2014-05-22
申请号：US14016951
申请日：2013-09-03
Applicant: ARRAY BIOPHARMA, INC. , VENTIRX PHARMACEUTICALS, INC.
Inventor： James Jeffry Howbert , Gregory Dietsch , Robert M. Hershberg , Laurence E. Burgess , George A. Doherty , C. Todd Eary , Robert D. Groneberg , Zachary Jones
IPC: C07D403/14 , C07D223/16 , C07D401/04 , C07D403/04 , C07D403/10 , C07D401/14
CPC classification number: C07D223/16 , A61K31/4025 , A61K31/55 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/14
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
-
公开(公告)号：US09655904B2
公开(公告)日：2017-05-23
申请号：US14817291
申请日：2015-08-04
Applicant: VentiRx Pharmaceuticals, Inc. , Array BioPharma, Inc.
Inventor： James Jeffry Howbert , Gregory Dietsch , Robert Hershberg , Laurence E. Burgess , Joseph P. Lyssikatos , Brad Newhouse , Hong-Woon Yang
IPC: A01N43/00 , A61K31/55 , C07D223/14 , C07D401/12 , C07D401/14 , C07D403/10 , C07D223/16 , C07D401/04 , C07D405/04 , C07D405/10
CPC classification number: A61K31/55 , C07D223/14 , C07D223/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/04 , C07D405/10
Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.
-
公开(公告)号：US20160331758A1
公开(公告)日：2016-11-17
申请号：US14977129
申请日：2015-12-21
Applicant: VentiRx Pharmaceuticals, Inc.
Inventor： J. Jeffry Howbert , Muralikrishna Duvvuri , Robert Hershberg , Gregory Dietsch
CPC classification number: A61K31/55 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/724 , A61K47/40 , A61K47/6951 , B82Y5/00 , C07D223/16 , C08B37/0012 , Y02A50/393
Abstract: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
Abstract translation: 本发明一般涉及用于治疗癌症，优选实体瘤和淋巴瘤的TLR激动剂，优选TLR7或TLR8激动剂的稳定制剂。 具体地，本发明涉及高达50mg / ml的包含环糊精的TLR激动剂的稳定制剂。
-
-
-
-
-
-
-
-
-
Search Results
190
records
(took 0.031 seconds)
